Tonix Pharmaceuticals Files 8-K

Ticker: TNXP · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1430306

Sentiment: neutral

Topics: corporate-info, filing

Related Tickers: TNXP

TL;DR

Tonix Pharma updated its corporate info & office address in NJ.

AI Summary

Tonix Pharmaceuticals Holding Corp. filed an 8-K on January 8, 2025, reporting on other events and financial statements. The filing indicates the company's principal executive offices are located at 26 Main Street, Suite 101, Chatham, New Jersey 07928, with a business phone number of (862) 904-8182. The company was incorporated in Nevada and previously operated under the name Tamandare Explorations Inc. before a name change on March 20, 2008.

Why It Matters

This 8-K filing provides updated corporate information and location details for Tonix Pharmaceuticals, which is relevant for investors and stakeholders tracking the company's official presence and administrative structure.

Risk Assessment

Risk Level: low — This filing is primarily administrative and does not contain new material financial or operational information that would significantly alter risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a current report for Tonix Pharmaceuticals Holding Corp., detailing other events and including financial statements and exhibits.

Where are Tonix Pharmaceuticals' principal executive offices located?

The principal executive offices of Tonix Pharmaceuticals Holding Corp. are located at 26 Main Street, Suite 101, Chatham, New Jersey 07928.

What is the telephone number for Tonix Pharmaceuticals?

The registrant's telephone number, including area code, is (862) 904-8182.

When did Tonix Pharmaceuticals change its name?

Tonix Pharmaceuticals Holding Corp. changed its name from Tamandare Explorations Inc. on March 20, 2008.

In which state was Tonix Pharmaceuticals Holding Corp. incorporated?

Tonix Pharmaceuticals Holding Corp. was incorporated in Nevada.

Filing Stats: 903 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2025-01-08 07:39:03

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 8, 2025, Tonix Pharmaceuticals Holding Corp. (the "Company") announced the appointment of Gary Ainsworth as Vice President, Market Access. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. The Company updated its investor presentation, which is used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.02 hereto and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.01 and 99.02 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On January 8, 2025, the Company announced the appointment of Gary Ainsworth as Vice President, Market Access. The Company provided updated guidance on the timing of topline data for two of its programs: topline data for the Phase 2 study of the Company's TNX-1300 product candidate for cocaine intoxication is expected in the third quarter of 2025; and topline data for the Phase 1 study of the Company's TNX-1500 product candidate for the prevention of kidney transplant rejection is expected in the first quarter of 2025. Forward- Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 99.02 104 Press Release of the Company, January 8, 2025 Corporate Presentation by the Company for January 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: January 8, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing